708 related articles for article (PubMed ID: 22473169)
21. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
Rajeswaran A; Trojan A; Burnand B; Giannelli M
Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
[TBL] [Abstract][Full Text] [Related]
22. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
[TBL] [Abstract][Full Text] [Related]
23. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
Schmid-Bindert G; Engel-Riedel W; Reck M; Schuette W; Stöhlmacher J; Fischer JR; Mazières J; Chouaid C; Wolf M; Vinolas N; Soldatenkova V; Ripoche V; Nguyen T; Visseren-Grul C
Lung Cancer; 2015 Dec; 90(3):397-404. PubMed ID: 26791798
[TBL] [Abstract][Full Text] [Related]
24. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
25. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
[TBL] [Abstract][Full Text] [Related]
28. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
[TBL] [Abstract][Full Text] [Related]
29. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer.
Couillard-Montminy V; Gagnon PY; Fortin S; Côté J
J Oncol Pharm Pract; 2019 Jan; 25(1):44-51. PubMed ID: 28825377
[TBL] [Abstract][Full Text] [Related]
31. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
33. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.
Grossi F; Rijavec E; Genova C; Barletta G; Biello F; Maggioni C; Burrafato G; Sini C; Dal Bello MG; Meyer K; Roder J; Roder H; Grigorieva J
Br J Cancer; 2017 Jan; 116(1):36-43. PubMed ID: 27898657
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
[TBL] [Abstract][Full Text] [Related]
36. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
37. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Soria JC; Tan DSW; Chiari R; Wu YL; Paz-Ares L; Wolf J; Geater SL; Orlov S; Cortinovis D; Yu CJ; Hochmair M; Cortot AB; Tsai CM; Moro-Sibilot D; Campelo RG; McCulloch T; Sen P; Dugan M; Pantano S; Branle F; Massacesi C; de Castro G
Lancet; 2017 Mar; 389(10072):917-929. PubMed ID: 28126333
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
Ardizzoni A; Boni L; Tiseo M; Fossella FV; Schiller JH; Paesmans M; Radosavljevic D; Paccagnella A; Zatloukal P; Mazzanti P; Bisset D; Rosell R;
J Natl Cancer Inst; 2007 Jun; 99(11):847-57. PubMed ID: 17551145
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]